The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A New Administration Brings Updated ACR Policy Positions

A New Administration Brings Updated ACR Policy Positions

March 1, 2017 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The ACR continues to broaden its advocacy efforts on issues critical to rheumatology, as described in updates to its 2017 health policy statements. Along with continuing to advocate for access to care and treatments, enhancements to rheumatology research and training the next generation of rheumatologists, the 2017 health policy statements address a number of new policies deemed critical for the practice of rheumatology in the ever-evolving healthcare landscape.

You Might Also Like
  • Shifting Health Policy Landscape Brings Opportunities, Responsibility to Advocate for Rheumatology
  • AHCA, ACR Health Policy & More
  • The ACR’s Advocacy Leadership Conference Brings Volunteers to Washington, D.C.
Also By This Author
  • Research Into Causes of Systemic Vasculitis May Lead to Targeted Treatments Say Rheumatologists at the 2013 ACR/ARHP Annual Meeting

According to Angus Worthing, MD, chair of the ACR’s Government Affairs Committee (GAC), key advocacy areas in 2017 include: 1) MACRA implementation issues; 2) the debate around healthcare reform in the 115th Congress; and 3) the approval and use of biosimilars.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

MACRA Implementation
Kwas Huston, MD, a member of the GAC, highlighted the following specific positions supported by the ACR for MACRA implementation:

  • The need for simplicity and transparency to ensure that rheumatologists understand and can navigate both MACRA pathways (i.e., Merit-Based Incentive Payment System [MIPS] and Alternative Payment Models [APMs]);
  • The need to reduce administrative burdens associated with MACRA;
  • The need to not hold rheumatologists accountable for costs beyond their control (i.e., the price of biologics); and
  • The need to ensure participation in qualified clinical data registries, such as the Rheumatology Informatics System for Effectiveness (RISE) Registry, will count toward MIPS requirements.

Ensuring patient access to important treatment is a key area of advocacy, according to Dr. Worthing. The ACR “cautions Medicare that including the cost of expensive medicines in any reimbursement or penalty calculation may reduce patient access to important treatments,” he says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Healthcare Reform, Biosimilars & More

Dr. Worthing says the ACR continues to support:

  • Repeal of the Independent Payment Advisory Board (IPAB) provision of the Patient Protection & Affordable Care Act;
  • Minimization of the administrative burden through universal prior authorization in the case of multistate insurance plans;
  • Maintaining the Food and Drug Administration’s (FDA’s) authority to approve safe, effective biosimilars that can encourage market-based relief from the high costs of biologic arthritis drugs;
  • Adequate reimbursement for rheumatology services, as well as loan payments (particularly considering the impending workforce shortage);
  • Inclusion of safe, affordable medications in formularies;
  • Allowing multiple doctors to use chronic care management codes;
  • FDA funding and hiring reforms, specifically for the evaluation of biosimilars;
  • The allocation of $20 million from the Department of Defense for dedicated arthritis research; and
  • The inclusion of valid, methodologically sound and meaningful comparative effectiveness data in FDA drug labels.

Along with focusing advocacy in 2017 on these updated policies, Dr. Worthing says the ACR remains committed to advocating for robust rheumatology research, training of the future rheumatology workforce and innovative methods to curb the high price of biologics.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Legislation & Advocacy, Practice Management, Professional Topics Tagged With: 115th Congress, Biosimilars, health policy, health policy statement, Healthcare Reform, MACRA implementation

You Might Also Like:
  • Shifting Health Policy Landscape Brings Opportunities, Responsibility to Advocate for Rheumatology
  • AHCA, ACR Health Policy & More
  • The ACR’s Advocacy Leadership Conference Brings Volunteers to Washington, D.C.
  • ACR Leaders to Talk Policy with Congressional Leaders in D.C.

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.